Corporation
AbbVie Corporation
- Meetings this Parliament
- 39
- With MPs
- 14
- Since Nov 2021
- 105
- Active registrations
- 1
Most recent reported meeting: Sep 23, 2026.
Lobbying by AbbVie Corporation: its registrations, its lobbyists, the bills it has named and every meeting it has reported with federal office holders since November 2021.
← LobbyingRegistrations in effect
In-house (corporation) In effect since Jul 2, 2026
Filed by Tanusree Misra, Vice-President and General Manager
Lobbyists
- Adam Cook · Manager, Market Access and Government Affairs, Ontario & Federal Programs
- Amelie McFadyen · Manager, Government Affairs and Policy
- Arima Ventin · Head, Market Access and Government Affairs
- Dana Corsen · Field Lead, Market Access & Government Affairs, Immunology
- David Link · Field Lead, Market Access & Government Affairs - Specialty
- Eric Pegolo · Manager, Market Access and Government Affairs, Ontario
- Harold Just · Manager, Market Access and Government Affairs - Oncology
- Herve Gaboury · Head, Market Access & HEOR, Oncology
- Jean-Luc Fortier · Manager, Market Access and Government Affairs, Quebec
- Jeff Onyskiw · Sr Manager, Market Access & Government Affairs – Saskatchewan, Manitoba, Federal Plans, Territories
- Judith Mergl · Director, Regulatory Affairs
- Lauren Fischer · Lead, Government Affairs & Policy
- Reema Malhotra · Field Lead, Market Access & Government Affairs - Oncology
- Sean Awalt · Manager, Market Access and Government Affairs, Atlantic
- Stephanie Sauvageau · Head, Medical Affairs
- Tanusree Misra · Vice-President and General Manager
Institutions they may lobby: Atlantic Canada Opportunities Agency (ACOA), Canadian Institutes of Health Research (CIHR), Correctional Service of Canada (CSC), Employment and Social Development Canada (ESDC), Finance Canada (FIN), Global Affairs Canada (GAC), Health Canada (HC), House of Commons, Immigration and Refugee Board (IRB), Indigenous Services Canada (ISC), Innovation, Science and Economic Development Canada (ISED), Intergovernmental Affairs Secretariat (IGA), Invest in Canada Hub, National Defence (DND), National Research Council (NRC), Patented Medicine Prices Review Board (PMPRB), Prime Minister's Office (PMO), Privy Council Office (PCO), Public Health Agency of Canada (PHAC), Public Services and Procurement Canada (PSPC), Royal Canadian Mounted Police (RCMP), Senate of Canada, Treasury Board Of Canada Secretariat (TBS), Veterans Affairs Canada (VAC)
What they're lobbying on (19)Hide details
- Communications regarding opportunities to speed patient access to live-saving medicines on publicly-funded drug formularies in Canada by reducing red tape.
- Innovation, Science and Economic Development (ISED)'s Health Emergency Readiness program, insofar as it pertains to growth and development of the life sciences industry in Canada.
- Communication regarding free trade agreements as they relate to the biopharmaceutical industry.
- The pan Canadian Pharmaceutical Alliance (pCPA) with respect to public formulary listing of new medicines, insofar as the federal government is a participating jurisdiction and holds a seat on the Board of Directors.
- Public Health Agency of Canada, regarding the federal response to the hepatitis C virus.
- Patented Medicine Prices Review Board (PMPRB) Guidelines with regard to prices charged by Rights Holders for patented medicines sold in Canada.
- Federal Government Non Insured Health Benefits program with respect to reimbursement of a prescription medicine and changes in type of reimbursement
- Engagement with Health Canada’s Regulatory Operations & Enforcement branch regarding supply chain resilience & integrity; mitigating and alleviating drug shortages.
- Communications with Heath Canada regarding modernization of the medical devices regulatory framework.
- Communications with Health Canada regarding the evolution of the regulatory framework to address advanced therapeutic products.
- Communications with Health Canada regarding the application of its nitrosamine guidelines.
- Communications with Health Canada regarding modernization of clinical trials regulations, including diversity and inclusivity of clinical trials.
- Communications with Health Canada regarding guidelines for pediatric action plans.
- Communications regarding the value assessment of new medicines by Canada's Drug Agency (CDA) and the design of proposed new work streams, insofar as the federal government is a funder and holds a seat on the Board of Directors.
- Communications regarding the design and implementation of the federal Drugs for Rare Diseases strategy.
- Communications regarding national pharmacare legislation, regulations, policies or programs.
- Communications regarding intellectual property protection of prescription drugs, including the Patent Act, the Patented Medicines Regulations, the Patented Medicine Notice of Compliance (PMNOC) Regulations, the Patent Term Adjustment regime and Health Canada’s Data Protection regime.
- Communications regarding Health Canada's Regulatory Innovation Agenda regarding proposed regulatory amendments and guidelines to enable agile licensing of drugs and medical devices.
- Communications regarding access to and approval of medicines addressing the growing public health threat of antimicrobial resistance.
Registration 965103-15270-50. Look it up in the official Registry
Reported meetings
SpreadsheetFiled by Tracey Ramsay (50), Rami Fayed (29), Tanusree Misra (17), Arima Ventin (9).
-
Reported by Tracey Ramsay · In-house (corporation)
- Darryl Patterson · Director General, Innovation, Science and Economic Development Canada (ISED)
- Rodrigo Arancibia · Director, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by Tracey Ramsay · In-house (corporation)
- Sandenga Yeba · Senior Policy Advisor, Health Canada (HC)
HealthIndustry
-
Reported by Tracey Ramsay · In-house (corporation)
- Sandenga Yeba · Senior Policy Advisor - Quebec Desk, Health Canada (HC)
HealthIndustry
-
Reported by Tracey Ramsay · In-house (corporation)
- Tyler Norman · Regional Advisor, Innovation, Science and Economic Development Canada (ISED)
HealthIndustry
-
Reported by Tracey Ramsay · In-house (corporation)
- Dylan Marando · Senior Policy Advisor, Prime Minister's Office (PMO)
Health
From the Office of the Commissioner of Lobbying's open data, published November 5, 2026. Reports cover oral, arranged meetings with designated public office holders since November 22, 2021; lobbyists file them by the 15th of the following month. Names of MPs are matched to the current House of Commons, and bills are linked when the lobbyist's own description makes clear which bill it means. Contains information licensed under the Open Data Licence Agreement — Office of the Commissioner of Lobbying. Licence. PolitiKit is independent and is not endorsed by the Commissioner of Lobbying.